Hello Bio announces the launch of novel water-soluble and highly potent hM3Dq & hM4Di ligands – exciting compounds for scientists studying GPCR and DREADD signalling. Hello Bio has been granted a licence from the National Institute on Drug Abuse and the National Institute of Neurological Disorders and Stroke, both institutes of the National Institutes of Health, as well as Johns Hopkins University, to manufacture these novel compounds and make them commercially available to life scientists worldwide.

JHU37160 dihydrochloride and JHU37152 dihydrochloride are novel DREADD ligands with high potency at hM3Dq and hM4Di DREADDs in in vitro functional assays. Both JHU37160 and JHU37152 also have high affinity for hM4Di and hM3Dq. They are active in vivo, following ip administration, and are available from Hello Bio as both the water-soluble dihydrochloride salts, and freebase forms. They are sold for preclinical purposes under an intellectual property licence from the NIH and JHU (United States Provisional Patent Application No. 62/627,527).

We are delighted to have been granted a licence to intellectual property from the National Institutes of Health and Johns Hopkins University to make these novel DREADDs ligands JHU37160 and JHU37152 available to the scientific research community. Our chemists have used their expertise in DREADDs to manufacture these products at high purity (>98%), in water-soluble and freebase forms, enabling researchers to use them with confidence in their experiments.

These new compounds join Hello Bio’s unique range of DREADD ligands which includes clozapine N-oxide dihydrochloride (water soluble), DREADD agonist 21 (Compound 21) dihydrochloride (water-soluble) and perlapine dihydrochloride (water-soluble). We hope that JHU37160 and JHU37152 will contribute to further pushing this exciting field of research forwards.

Steve Roome PhD, Managing Director and Founder, Hello Bio